Citius Pharmaceuticals, INC. (CTXR) — SEC Filings

Q: What are the key financial highlights for Citius Pharmaceuticals, INC.?

Key financial highlights for Citius Pharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Citius Pharmaceuticals, INC.?

Key executives at Citius Pharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Citius Pharmaceuticals, INC. stock?

Risk factors for Citius Pharmaceuticals, INC. (CTXR) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Citius Pharmaceuticals, INC.?

Forward-looking statements and predictions from Citius Pharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Citius Pharmaceuticals, INC.. Recent 8-K filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Citius Pharmaceuticals, INC. on SEC EDGAR

Overview

Citius Pharmaceuticals, INC. (CTXR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 23, 2025: Citius Pharmaceuticals, Inc. (CTXR) launched LYMPHIR in December 2025 through its majority-owned subsidiary, Citius Oncology, marking its transition to a commercial company. The company reported a market value of voting and non-voting common equity held by non-affiliates of approximately $11,390,000

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Citius Pharmaceuticals, INC. is neutral.

Filing Type Overview

Citius Pharmaceuticals, INC. (CTXR) has filed 37 8-K, 1 10-K, 6 10-Q, 1 DEF 14A, 1 10-K/A, 1 SC 13D/A, 1 SC 13G/A, 1 SC 13G, 1 DEFA14A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

8-K Filing — 8-K · Apr 6, 2026
Citius Pharma Goes Commercial with LYMPHIR Launch, Faces Going Concern Doubt — 10-K · Dec 23, 2025 Risk: high
Citius Pharmaceuticals, Inc. (CTXR) launched LYMPHIR in December 2025 through its majority-owned subsidiary, Citius Oncology, marking its transition to a commer
8-K Filing — 8-K · Dec 1, 2025
Citius Pharmaceuticals Files 8-K — 8-K · Oct 23, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorpo
Citius Pharmaceuticals Files 8-K — 8-K · Oct 21, 2025 Risk: medium
On October 20, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial state
Citius Pharma's Q2 Loss Widens Amid R&D Spend — 10-Q · Aug 12, 2025 Risk: high
Citius Pharmaceuticals, Inc. (CTXR) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical compan
Citius Pharmaceuticals Files 8-K — 8-K · Jul 8, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, reporting on other events and financial statements/exhibits. The filing date is July 8, 2025, with th
Citius Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jun 12, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on June 9, 2025, the entry into a material definitive agreement. The company, incorporated in Nevada, filed an 8-K report
Citius Pharma Files 8-K on Security Holder Rights & Bylaws — 8-K · Jun 9, 2025 Risk: medium
Citius Pharmaceuticals, Inc. filed an 8-K on June 9, 2025, reporting on several items including material modifications to security holder rights, amendments to
Citius Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jun 3, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on June 2, 2025, that it has entered into a material definitive agreement. This agreement creates a direct financial obli
Citius Pharmaceuticals Faces Delisting Notice — 8-K · May 30, 2025 Risk: high
Citius Pharmaceuticals, Inc. filed an 8-K on May 29, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorpor
Citius Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
Citius Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Nevada, is focused on pha
Citius Pharma Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed its Definitive Proxy Statement (DEF 14A) on April 28, 2025, for its annual meeting on June 9, 2025. The filing concerns the s
Citius Pharmaceuticals Files 8-K: Agreements, Equity Sales, Bylaw Changes — 8-K · Apr 18, 2025 Risk: medium
On April 16, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
Citius Pharmaceuticals Enters Material Definitive Agreement — 8-K · Apr 3, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on March 28, 2025, that it entered into a material definitive agreement. The filing does not provide specific details abo
Citius Pharmaceuticals Enters Material Definitive Agreement — 8-K · Apr 2, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on April 1, 2025, that it has entered into a material definitive agreement. The company, incorporated in Nevada, is invol
Citius Pharma Files 8-K on Shareholder Votes — 8-K · Mar 10, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on March 10, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
Citius Pharmaceuticals Files 10-Q for Q4 2024 — 10-Q · Feb 14, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in Nevada, is involved in the pharmaceut
Citius Pharmaceuticals Files 8-K — 8-K · Feb 6, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The company, incorporated in Nevada, has its pri
Citius Pharma Files 10-K/A Amendment — 10-K/A · Jan 27, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an amendment (10-K/A) on January 27, 2025, for their fiscal year ending September 30, 2024. The company, previously known as
Citius Pharmaceuticals Files 8-K — 8-K · Jan 8, 2025 Risk: medium
On January 7, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statem
Citius Pharmaceuticals Files 8-K with Exhibits — 8-K · Jan 7, 2025 Risk: low
On January 7, 2025, Citius Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no
Citius Pharmaceuticals Files 8-K on Financials — 8-K · Dec 27, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on December 27, 2024, reporting on its results of operations and financial condition. The filing also includes financi
Citius Pharma Sells Mino-Lok to NovaBay for $10M Upfront — 8-K · Dec 20, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on December 18, 2024, that it has entered into a definitive agreement to sell its Mino-Lok® product candidate to NovaBay
Mazur Amends Citius Pharma 13D Filing — SC 13D/A · Nov 27, 2024 Risk: medium
Leonard L. Mazur filed an amendment (No. 2) to Schedule 13D on November 27, 2024, regarding Citius Pharmaceuticals, Inc. The filing indicates a change in the da
Citius Pharmaceuticals Files 8-K on Security Holder Rights — 8-K · Nov 26, 2024 Risk: medium
Citius Pharmaceuticals, Inc. filed an 8-K on November 25, 2024, reporting material modifications to the rights of security holders and other events. The filing
Citius Pharmaceuticals Files 8-K — 8-K · Nov 25, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on November 25, 2024, reporting other events and financial statements. The filing does not contain specific details ab
Citius Pharmaceuticals Files 8-K: Material Agreement Announced — 8-K · Nov 18, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on November 15, 2024, that it has entered into a material definitive agreement. The company also reported other events an
Citius Pharma Faces Nasdaq Delisting Risk — 8-K · Nov 13, 2024 Risk: high
Citius Pharmaceuticals, Inc. announced on November 6, 2024, that it received a notification from the Nasdaq Stock Market indicating a failure to meet the minimu
Citius Pharmaceuticals Files 8-K — 8-K · Nov 12, 2024 Risk: medium
Citius Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, reporting "Other Events" and "Financial Statements and Exhibits" as of November 11, 2024. The fi
Citius Pharma Enters Material Definitive Agreement — 8-K · Sep 27, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on September 25, 2024, that it entered into a material definitive agreement. The filing does not disclose specific detail
Citius Pharmaceuticals Enters Material Definitive Agreement — 8-K · Sep 13, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on September 9, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details
Citius Pharma Faces Nasdaq Delisting Warning — 8-K · Sep 11, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on September 10, 2024, that it received a notification from the Nasdaq Stock Market regarding its failure to meet the min
Citius Pharmaceuticals Files 8-K — 8-K · Sep 5, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on September 5, 2024, reporting other events and financial statements. The company, incorporated in Nevada, has its pr
Citius Pharma Secures Loan Agreement with Innoviva — 8-K · Aug 16, 2024 Risk: medium
On August 12, 2024, Citius Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Loan and Security Agreement with Innoviva, Inc. Th
Citius Pharmaceuticals Files Q2 2024 10-Q Report — 10-Q · Aug 12, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Nevada, is involved in the
Citius Pharmaceuticals Files 8-K — 8-K · Aug 8, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on August 8, 2024, to report other events and financial statements. The filing does not contain specific details about
Citius Pharmaceuticals Files 8-K — 8-K · May 21, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on May 21, 2024, to report other events and financial statements. The filing does not contain specific details about n
Citius Pharmaceuticals, Inc. Files Quarterly Report (10-Q) for Period Ended March 31, 2024 — 10-Q · May 14, 2024 Risk: low
Citius Pharmaceuticals, Inc. (CTXR) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Citius Pharmaceuticals, Inc. filed a 10-Q report for the quart
SC 13G/A Filing — SC 13G/A · May 8, 2024
Citius Pharmaceuticals Files 8-K, Enters Material Agreement — 8-K · Apr 30, 2024 Risk: medium
On April 25, 2024, Citius Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The c
Citius Pharma to Acquire NovaLead Pharma for $15M — 8-K · Apr 5, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on April 3, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of NovaLead Pharma Lt
Citius Pharmaceuticals Files 8-K — 8-K · Mar 18, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on March 18, 2024, to report other events and financial statements. The filing does not contain specific financial fig
Citius Pharmaceuticals Faces Delisting Concerns — 8-K · Mar 13, 2024 Risk: high
Citius Pharmaceuticals, Inc. filed an 8-K on March 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company also su
Citius Pharma Files 8-K on Financial Condition and Operations — 8-K · Feb 15, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing, under Commission File Number
Citius Pharmaceuticals, Inc. Files 10-Q for Period Ended December 31, 2023 — 10-Q · Feb 14, 2024 Risk: low
Citius Pharmaceuticals, Inc. (CTXR) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Citius Pharmaceuticals, Inc. filed a 10-Q report for the
BlackRock Discloses 5.0% Stake in Citius Pharmaceuticals — SC 13G · Jan 31, 2024
BlackRock Inc., a major investment firm, reported owning 5.0% of Citius Pharmaceuticals, Inc.'s Common Stock as of December 31, 2023. This filing, an SC 13G, in
Citius Pharma Files Definitive Additional Proxy Materials — DEFA14A · Jan 26, 2024
Citius Pharmaceuticals, Inc. filed a DEFA14A on January 26, 2024, indicating they are providing definitive additional materials related to a proxy statement. Th
Citius Pharma Files 8-K on 'Other Events' & Financial Exhibits — 8-K · Jan 23, 2024
Citius Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing indicates that th
Citius Pharma Adopts Shareholder Proxy Access for Director Nominations — 8-K · Jan 5, 2024
Citius Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, to announce that it will allow shareholders to nominate directors for its board using the company'

Risk Profile

Risk Assessment: Of CTXR's 43 recent filings, 5 were flagged as high-risk, 20 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Citius Pharmaceuticals, INC.'s most recent 10-K filing (Dec 23, 2025):

Revenue: $0
Net Income: N/A
EPS: N/A
Debt-to-Equity: N/A
Cash Position: N/A
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

Leonard L. Mazur

Industry Context

Citius Pharmaceuticals operates in the biopharmaceutical sector, focusing on critical care products with a strategy of reformulating existing drugs to reduce development risk. The industry is characterized by high R&D costs, stringent regulatory hurdles, and significant competition from established players. Companies often seek to address unmet medical needs in areas like oncology and anti-infectives, aiming for intellectual property and regulatory exclusivity to gain market advantage.

Top Tags

material-agreement (10) · filing (7) · pharmaceuticals (7) · financials (5) · 8-K (5) · corporate-governance (5) · 10-Q (5) · sec-filing (5) · compliance (4) · regulatory-filing (4)

Key Numbers

Market value of non-affiliate common equity: $11.39M — As of March 31, 2025, indicating company size
Shares of common stock outstanding: 20,762,917 — As of December 17, 2025, reflecting current share count
Citius Pharma's ownership of Citius Oncology: 77.9% — As of December 17, 2025, post-Merger
Citius Pharma's initial ownership of Citius Oncology: 92% — Immediately after the August 2024 Merger closing
Fiscal Year End: September 30, 2025 — Reporting period for the 10-K filing
LYMPHIR Launch Date: December 2025 — Marks Citius Pharma's transition to a commercial company
Citius Oncology Merger Date: August 2024 — When Citius Oncology became a standalone publicly-traded company
Citius Pharma's ownership of NoveCite, Inc.: 75% — Ownership stake in the subsidiary developing ARDS therapy
Net Loss: $10.5M — Increased from $9.2M in Q2 2024, reflecting higher R&D spend.
Revenue: $0 — Consistent with pre-commercial stage, highlighting reliance on financing.
Mino-Lok Trial Stage: Phase 3 — Critical stage for lead product candidate, determining future commercial viability.
Annual Meeting Date: 20250609 — Date of the shareholder meeting for which proxies are being solicited.
Filing Date: 20250428 — Date the Definitive Proxy Statement was filed with the SEC.
Upfront Payment: $10.0M — Cash received by Citius Pharmaceuticals from NovaBay Pharmaceuticals for Mino-Lok®.
Compliance Period: 180 days — Timeframe to regain minimum bid price

Related Companies

CTOR · CTRS · NBY

Frequently Asked Questions

What are the latest SEC filings for Citius Pharmaceuticals, INC. (CTXR)?

Citius Pharmaceuticals, INC. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 37 8-K, 6 10-Q, 1 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CTXR filings?

Across 50 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Citius Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Citius Pharmaceuticals, INC. (CTXR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Citius Pharmaceuticals, INC.?

Key financial highlights from Citius Pharmaceuticals, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CTXR?

The investment thesis for CTXR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Citius Pharmaceuticals, INC.?

Key executives identified across Citius Pharmaceuticals, INC.'s filings include Leonard L. Mazur.

What are the main risk factors for Citius Pharmaceuticals, INC. stock?

Of CTXR's 43 assessed filings, 5 were flagged high-risk, 20 medium-risk, and 18 low-risk.

What are recent predictions and forward guidance from Citius Pharmaceuticals, INC.?

Forward guidance and predictions for Citius Pharmaceuticals, INC. are extracted from SEC filings as they are enriched.